These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 11243601)
1. Laboratory surrogates for anti-atherosclerotic drug development. Stein E Am J Cardiol; 2001 Feb; 87(4A):21A-26A. PubMed ID: 11243601 [TBL] [Abstract][Full Text] [Related]
2. Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development. Orloff DG Am J Cardiol; 2001 Feb; 87(4A):35A-41A. PubMed ID: 11243603 [TBL] [Abstract][Full Text] [Related]
3. Newer risk markers and surrogate endpoints in atherosclerosis management. Ballantyne CM Clin Cardiol; 2001 Aug; 24(8 Suppl):III13-7. PubMed ID: 11501598 [TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318 [TBL] [Abstract][Full Text] [Related]
6. Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. Kim HK; Chang SA; Choi EK; Kim YJ; Kim HS; Sohn DW; Oh BH; Lee MM; Park YB; Choi YS Int J Cardiol; 2005 Jun; 101(3):435-40. PubMed ID: 15907412 [TBL] [Abstract][Full Text] [Related]
8. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Kuvin JT; Dave DM; Sliney KA; Mooney P; Patel AR; Kimmelstiel CD; Karas RH Am J Cardiol; 2006 Sep; 98(6):743-5. PubMed ID: 16950175 [TBL] [Abstract][Full Text] [Related]
9. [High density lipoproteins and atherosclerosis]. Idzior-Waluś B; Waluś M; Foltyn A Przegl Lek; 2004; 61(12):1433-5. PubMed ID: 15850343 [TBL] [Abstract][Full Text] [Related]
10. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients. Kempen HJ; Gomaraschi M; Simonelli S; Calabresi L; Moerland M; Otvos J; Jeyarajah E; Kallend D; Wijngaard PLJ Atherosclerosis; 2016 Dec; 255():17-24. PubMed ID: 27816804 [TBL] [Abstract][Full Text] [Related]
11. Relation of clinical benefit to metabolic effects in lipid-lowering therapy. Herd JA Am J Cardiol; 1998 Sep; 82(6A):22M-25M. PubMed ID: 9766344 [TBL] [Abstract][Full Text] [Related]
12. [Lipid factors and evolution of the atherosclerotic plaque: review of recent trials]. Scardi S G Ital Cardiol; 1996 Dec; 26(12):1481-93. PubMed ID: 9162677 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study. Voros S; Joshi PH; Vazquez G; Roth G; Murrieta L; Rinehart S; Qian Z; Miller J J Cardiovasc Comput Tomogr; 2010; 4(3):164-72. PubMed ID: 20413364 [TBL] [Abstract][Full Text] [Related]
14. [Determination of the usefulness of selected biochemical parameters for assessing the advanced atheromatous changes in human coronary arteries]. Bukowska H Ann Acad Med Stetin; 1998; 44():29-43. PubMed ID: 9857530 [TBL] [Abstract][Full Text] [Related]
15. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). Arsenault BJ; Kohli P; Lambert G; DeMicco DA; Laskey R; Messig MM; Kastelein JJ; Waters DD Am J Cardiol; 2016 Aug; 118(4):494-8. PubMed ID: 27328952 [TBL] [Abstract][Full Text] [Related]
16. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Marschang P; Friedrich GJ; Ditlbacher H; Stoeger A; Nedden DZ; Kirchmair R; Dienstl A; Pachinger O; Patsch JR Int J Cardiol; 2006 Jan; 106(2):183-90. PubMed ID: 16321690 [TBL] [Abstract][Full Text] [Related]
17. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. Schiele F; Ecarnot F; Chopard R Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):88-100. PubMed ID: 28618915 [TBL] [Abstract][Full Text] [Related]
20. Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. Santos RD; Lorenzatti AJ; Barros CF; Escobar E; J Clin Lipidol; 2011; 5(3):124-132. PubMed ID: 21600516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]